论文部分内容阅读
目的:探讨血清CA72-4、CA19-9、CEA联合检测对胃癌的临床价值。方法:对32例中晚期胃癌患者和21例良性胃病患者采用放射免疫法(RIA)分别测定CA72-4、CA19-9和CEA。结果:胃癌组中CA72-4、CA19-9、CEA血清测定值水平、阳性率均明显高于良性胃病组(P < 0.01。其中胃癌组的CA72-4阳性率(59.4%明显高于CA19-9和CEA28.1%。联合检测时胃癌组中各种联合方式阳性率均明显高于良性胃病组,且良性胃病组阳性率不增加,其中胃癌组的联合检测CA72-4+CA19-9、CA72-4+CA19-9+CEA阳性率分别提高到68.8%和71.8%,均明显高于其他联合方式,如CA72-4+CEA(46.8%)、CA19-9+CEA(43.8%。但CA72-4+CA19-9和CA72-4+CA19-9+CEA之间无统计学差异(P >0.05。结论:以CA72-4+CA19-9或CA72-4+CA19-9+CEA联合检测可以提高胃癌的阳性检出率,但不增加良性胃病假阳性率,故对胃癌的早期诊断、疗效监测、预后、复发转移有重要意义。
Objective: To explore the clinical value of combined detection of serum CA72-4, CA19-9 and CEA in gastric cancer. METHODS: CA72-4, CA19-9, and CEA were measured by radioimmunoassay (RIA) in 32 patients with advanced gastric cancer and 21 patients with benign gastropathy. Results: The serum levels of CA72-4, CA19-9 and CEA in the gastric cancer group were significantly higher than those in the benign gastropathy group (P < 0.01). Among them, the CA72-4 positive rate in the gastric cancer group (59.4%). Significantly higher than CA19-9 and CEA28.1%.The positive rates of various combinations in the gastric cancer group were significantly higher than those in the benign gastropathy group when combined detection, and the positive rate of the benign gastropathy group did not increase, including the combination of gastric cancer groups. The positive rates of CA72-4+CA19-9 and CA72-4+CA19-9+CEA were increased to 68.8% and 71.8%, respectively, which were significantly higher than other combinations, such as CA72-4+CEA (46.8%) and CA19-9+CEA ( There was no statistical difference between CA72-4+CA19-9 and CA72-4+CA19-9+CEA (P>0.05 ).Conclusion: Take CA72-4+CA19-9 or CA72-4+CA19-9+C. A joint detection can improve the positive rate of gastric cancer, but benign stomach without increasing the false positive rate, so early diagnosis of gastric cancer, the efficacy of monitoring, prognosis, recurrence is important.